We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Halts Trial After Adverse Event, Takes Step Back in Hep C Race
BMS Halts Trial After Adverse Event, Takes Step Back in Hep C Race
August 15, 2012
Bristol-Myers Squibb (BMS) is suspending a Phase II trial of a promising new hepatitis C (HCV) drug candidate that would be part of a new generation of oral combination therapies due to safety concerns.